国邦医药前三季度净利6.7亿元，同比增长15.78%

Core Insights - Guobang Pharmaceutical (605507) reported a revenue of 4.47 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 1.17% [1] - The net profit attributable to shareholders reached 670 million yuan, marking a year-on-year increase of 15.78% [1] Financial Performance - Revenue for the first three quarters: 4.47 billion yuan, up 1.17% year-on-year [1] - Net profit attributable to shareholders: 670 million yuan, up 15.78% year-on-year [1]